The original success of the copyright undeniably transformed the pharmaceutical landscape, but investing in companies strongly reliant on unbranded versions presents a uncertain picture. Despite early profits were impressive, the cessation of patents and the emergence of discounted alternatives have eroded the customer base. Consequently, a thoroug